|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
|1.||Sieper, J: 72 articles (10/2015 - 02/2000)|
|2.||Braun, J: 69 articles (01/2016 - 02/2000)|
|3.||Sieper, Joachim: 67 articles (12/2015 - 01/2002)|
|4.||Braun, Jürgen: 52 articles (12/2015 - 02/2003)|
|5.||van der Heijde, Désirée: 50 articles (12/2015 - 03/2003)|
|6.||Inman, Robert D: 48 articles (06/2015 - 03/2003)|
|7.||Maksymowych, Walter P: 38 articles (01/2015 - 03/2002)|
|8.||Rudwaleit, M: 36 articles (03/2015 - 01/2001)|
|9.||Rudwaleit, Martin: 34 articles (09/2015 - 03/2003)|
|10.||Dougados, Maxime: 33 articles (12/2015 - 09/2002)|
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/01/2008 - "Medical therapy of ankylosing spondylitis has improved dramatically with the advent of anti-tumor necrosis factor therapy, but nonpharmacologic therapies have long been employed to treat the condition. "
06/01/2004 - "TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS). "
12/01/2012 - "TNF-alpha blocking agents are very effective in patients with ankylosing spondylitis (AS), but several cases of liver problems have been published. "
07/01/2010 - "Therapy of ankylosing spondylitis with tumor necrosis factor (TNF)-blockers is very effective in about 50% of patients. "
07/01/2011 - "Despite overall good efficacy of currently available treatment [nonsteroidal anti-inflammatory drugs, tumor necrosis factor (TNF) α inhibitors] for ankylosing spondylitis (AS) and other spondyloarthritides (SpAs), up to 40% of the treated patients do not achieve an acceptable clinical improvement during the therapy. "
|2.||TNFR-Fc fusion protein (etanercept)FDA Link
12/01/2011 - "Etanercept 50 mg weekly treatment of Chinese patients with active ankylosing spondylitis is convenient, fast-acting, highly effective, and well tolerated."
01/01/2004 - "In randomized, double-blind, placebo-controlled trials, subcutaneous etanercept 25mg twice weekly for 6-24 weeks significantly reduced disease activity in patients with active ankylosing spondylitis. "
04/01/2008 - "Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept."
12/01/2006 - "Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly."
01/01/2004 - "Etanercept therapy significantly improved health-related quality of life in patients with ankylosing spondylitis compared with placebo. "
|3.||infliximab (Remicade)FDA Link
01/01/2014 - "After initiation of infliximab therapy, statistically significant improvement was observed in disease activity scores [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for AS, Disease Activity Score 28 (DAS-28) for RA] after 2 and 6 months (p < 0.05). "
04/01/2003 - "Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system."
10/01/2007 - "Is low-dose infliximab every 8 weeks effective in treating ankylosing spondylitis?"
12/01/2006 - "Infliximab has been shown to be effective in the treatment of ankylosing spondylitis (AS) when treated in a dose of 5 mg/kg at 6 weekly intervals. "
04/06/2002 - "Our results show that treatment with infliximab is effective in patients with active ankylosing spondylitis. "
|4.||adalimumab (Humira)FDA Link
02/01/2014 - "Adalimumab is a fully human, anti-TNF monoclonal antibody of proven efficacy and safety in the treatment of the signs, symptoms and functional disability of ankylosing spondylitis (AS). "
01/01/2014 - "Adalimumab, a TNF-α antagonist, offers a significant improvement in ankylosing spondylitis and is considered to be less immunogenic and more tolerable than other TNF-α blockers. "
11/01/2013 - "At week 12, the patient's and physician's global assessment of disease activity, swollen joint count, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS) and erythrocyte sedimentation rate improved significantly in the adalimumab group compared with the baseline values and compared with placebo. "
07/01/2011 - "To compare the impact of ankylosing spondylitis (AS) on health-related quality of life (HRQL) and of adalimumab on initial and sustained improvement in HRQL for patients with active AS versus the general US population. "
07/01/2006 - "More patients in the adalimumab group (45.2% [94 of 208]) than in the placebo group (15.9% [17 of 107]) had at least a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index at week 12 (P < 0.001). "
|5.||Sulfasalazine (Azulfidine)FDA LinkGeneric
04/01/2006 - "Is sulfasalazine effective in ankylosing spondylitis? "
05/01/1990 - "The results suggest that sulphasalazine is effective for the treatment of patients with ankylosing spondylitis. "
05/01/1986 - "The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis."
01/01/2005 - "We evaluated randomised and quasi-randomised trials examining the efficacy of sulfasalazine on ankylosing spondylitis. "
01/08/1989 - "Observations claiming sulphasalazine to act as a remission inducing drug for ankylosing spondylitis have neither been confirmed nor ruled out by our experiences. "
|6.||Methotrexate (Mexate)FDA LinkGeneric
09/01/2007 - "Is methotrexate effective for the treatment of ankylosing spondylitis?"
11/01/2002 - "Is methotrexate effective in ankylosing spondylitis?"
05/01/2014 - "The aim of this study was to evaluate the efficacy of methotrexate (MTX) in the treatment of ankylosing spondylitis (AS). "
03/01/2007 - "No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial."
08/01/2004 - "Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial."
|7.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
11/01/2002 - "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) effects in Ankylosing Spondylitis (AS) are only suspensive but because of their rapid efficacy on inflammatory symptoms they are the first-line treatment in AS. "
12/01/2007 - "Non-steroidal anti-inflammatory agents (NSAIDs) remain the mainstay of treatment for ankylosing spondylitis (AS) though one recent trial suggests that continuous as opposed to on-demand use may be superior in preventing progression of structural damage. "
01/01/2010 - "Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study."
08/01/2001 - "To develop criteria for symptomatic improvement in patients with ankylosing spondylitis (AS), using outcome domain data from placebo-controlled clinical trials of nonsteroidal antiinflammatory drugs (NSAIDs). "
01/01/2014 - "Our objective was to evaluate the feasibility, safety, and efficacy of intravenous (IV) infusion of allogenic mesenchymal stem cells (MSCs) in ankylosing spondylitis (AS) patients who are refractory to or cannot tolerate the side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). "
|8.||Indomethacin (Indometacin)FDA LinkGeneric
02/01/1984 - "Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis."
06/03/1967 - "Based on the results of this study, it is suggested that the role of indomethacin in the management of ankylosing spondylitis be re-evaluated and that the daily therapeutic dose of this drug which has been heretofore recommended be decreased."
11/01/1990 - "188 patients of ankylosing spondylitis were treated with anti-rheumatic tablet compared with 30 patients with Indomethacin as control group. "
10/25/1985 - "Sustained-release indomethacin in the management of ankylosing spondylitis."
02/01/1984 - "The efficacy and tolerability of a new formulation of slow-release indomethacin tablet was compared in a double-blind cross-over manner with a conventional indomethacin capsule in 30 patients with ankylosing spondylitis. "
01/01/2009 - "Golimumab was also superior to placebo for improving the signs and symptoms of ankylosing spondylitis in the GO-RAISE study; significantly more golimumab than placebo recipients achieved a >or=20% improvement in the Assessment in Ankylosing Spondylitis (ASAS) criteria at week 14. "
09/01/2014 - "Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial."
04/01/2015 - "Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study."
06/01/2014 - "The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial."
06/01/2014 - "The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial."
01/01/2014 - "Patients with <4 years and ≥4 years of disease were compared for improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS), C-reactive protein (CRP) and magnetic resonance imaging (MRI) score for sacroiliac joints (SIJ). "
11/01/2010 - "Parameters at baseline/1-year follow-up were: C-reactive protein (CRP): 14 (7-27)/5 (2-10) mg/l, BASDAI 59 (44-72)/21 (8-39) mm, Bath Ankylosing Spondylitis Functional Index (BASFI) 50 (34-67)/24 (9-45) mm, Bath Ankylosing Spondylitis Metrology Index 40 (20-50)/20 (10-40) mm. Within 6 months, 407/644 patients (63%) achieved a clinical response. "
06/01/2015 - "The aim of this study was to assess discriminant validity of Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-reactive protein (-CRP) and ASDAS-erythrocyte sedimentation rate (-ESR) and to compare with The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as clinical tools for the measurement of disease activity in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). "
07/01/2012 - "At the same time, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Patient Global Score (BAS-G) levels were measured, and physical examinations were performed on study participants to determine their extent of physical mobility. "
06/01/2012 - "The objective of this study is to evaluate the role of MMP-3 and MRI in assessing disease activity in sacroiliac joints of AS patients in comparison to the conventional measures Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). "
09/01/2014 - "Exercise is considered a fundamental tool for the management of ankylosing spondylitis (AS), in combination with pharmacological therapy that with the advent of biological therapy has improved dramatically the control of signs and symptoms of this challenging disease. "
03/01/2014 - "The likelihood of continued remission after the cessation of a biological therapy is much lower in ankylosing spondylitis."
01/01/2015 - "By this study, we aimed to compare Assessment in Ankylosing Spondylitis Response Criteria 20 response patterns (ASAS20) between subcutaneous approved biological agents in patients affected by ankylosing spondylitis by means of a mixed treatment comparison of different randomized controlled trials (RCTs) on the efficacy of biological therapies. "
01/01/2012 - "To compare ASAS (Assessment in Ankylosing Spondylitis Response Criteria), 20 response patterns between anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison of different randomized, controlled trials (RCTs) on the efficacy of biological therapies. "
03/01/2010 - "[Management of the patient with ankylosing spondylitis (AS) in partial remission with biologic therapy: is it possible to suspend treatment?]."
08/01/2009 - "Functional outcome was improved after lumbar closing wedge osteotomy in ankylosing spondylitis."
04/01/2013 - "Electronic databases and reference lists of key articles were searched to identify studies comparing effectiveness and safety outcomes between adult patients with ankylosing spondylitis who received closing wedge versus opening wedge osteotomies. "
04/01/2013 - "Study Rationale To seek out and assess the best quality evidence available comparing opening wedge osteotomy (OWO) and closing wedge osteotomy (CWO) in patients with ankylosing spondylitis to determine whether their results differ with regard to several different subjective and objective outcome measures. "
01/01/2008 - "The object of this study was to assess the effectiveness of preoperative planning in the restoration of balance and view angle in patients treated with lumbar osteotomy in ankylosing spondylitis (AS). "
01/01/2006 - "The following study describes a technique for preoperative planning and computer-assisted correction osteotomy in the treatment of ankylosing spondylitis. "
07/01/2005 - "This study is designed to show the efficacy of balneotherapy and balneotherapy (BT) + nonsteroid antiinflammatory drug (NSAID) use in Ankylosing spondylitis (AS) patients. "
10/01/2010 - "This study aimed to determine the effects of balneotherapy on disease activity, functional status, metrology index, pulmonary function and quality of life in patients with ankylosing spondylitis (AS). "
10/01/2010 - "The effects of balneotherapy on disease activity, functional status, pulmonary function and quality of life in patients with ankylosing spondylitis."
07/01/2006 - "The effect of balneotherapy on patients with ankylosing spondylitis."
07/01/2005 - "Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy."
01/01/2013 - "Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis metrology index (BASMI), ESR and CRP expression levels were compared before treatment, 12 h after treatment and 24 h after treatment. "
04/19/2011 - "The radiological assessments of mSASSS (modified Stoke ankylosing spondylitis spine score) were recorded at baseline, 3, 6 & 12 months after treatment. "
11/01/2009 - "Before and after treatment, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was measured, and all patients completed the International Index of Erectile Function (IIEF) questionnaire, a self-administered measure of sexual dysfunction with five domains: erectile function (EF), intercourse satisfaction (IS), orgasmic function (OF), sexual desire (SD) and overall satisfaction (OS). "
04/01/2007 - "Readers scored each set of MRI 3 times, using 3 different methods including the Ankylosing Spondylitis spine Magnetic Resonance Imaging-activity [ASspiMRI-a, grading activity (0-6) per vertebral unit in 23 units]; the Berlin modification of the ASspiMRI-a; and the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system, which scores the 6 vertebral units considered by the reader as the most abnormal, with additional scores for "depth" and "intensity." Both the order of the methods used by each reader and the timepoints (before/after treatment) were randomized. "
10/01/2010 - "The patients were evaluated using the global index, Bath ankylosing spondylitis disease activity index (BASDAI), disease functional index (BASFI), metrology index (BASMI), chest expansion measures, pulmonary function testing, and the medical outcomes study-short form-36 Health Survey (SF-36) (measure of quality of life) before balneotherapy and 1 month after treatment. "
|5.||Drug Therapy (Chemotherapy)
07/01/2007 - "To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice. "
07/01/2007 - "Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion."
01/01/1996 - "Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device."
06/04/1991 - "[Drug therapy of ankylosing spondylitis]."
08/05/1982 - "The necessity of balneophysical therapy in ankylosing spondylitis is emphasized, which in most cases will only be possible in combination with adequate drug therapy."